Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Mar 28:2018:bcr2016216746.
doi: 10.1136/bcr-2016-216746.

Drug-induced movement disorder and confusion associated with duloxetine

Sarah Hasan Siddiqui  1 , Nadeem Ahmed Memon  1 , Ravi Shanker  1
Affiliations
Case Reports

Drug-induced movement disorder and confusion associated with duloxetine

Sarah Hasan Siddiqui et al. BMJ Case Rep. .

Abstract

A 60-year-old woman with major depressive disorder, developed high blood pressure, confusion and dyskinesias of face, neck and jaw, following an increase in her dose of duloxetine. Routine blood tests including toxic, infective and metabolic workup were unremarkable. Cerebrospinal fluid analysis and electroencephalogram were also normal. MRI brain showed bilaterally symmetrical diffusion-restricted areas in deep cerebral white matter. Duloxetine was held on suspicion of drug adverse effect. She had complete resolution of symptoms within 48 hours and resolution of MRI brain changes over 6 weeks. Serotonin norepinephrine reuptake inhibitors such as duloxetine may have the potential to cause drug-induced movement disorders, confusion and high blood pressure and should be used cautiously especially in elderly.

Keywords: hypertension; neurology (drugs and medicines); unwanted effects / adverse reactions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
MRI brain, diffusion weighted imaging axial section showing hyperintense signals in bilateral deep white matter.
Figure 2
Figure 2
MRI brain, apparent diffusion coefficient sequence, axial section showing signal drop out in the regions corresponding to hyperintense signals on diffusion weighted imaging.
See this image and copyright information in PMC

References

    1. Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci 2014;11:37. - PMC - PubMed
    1. Kajdasz DK, Iyengar S, Desaiah D, et al. . Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007;29(Suppl):2536–46. 10.1016/j.clinthera.2007.12.002 - DOI - PubMed
    1. Arnold LM, Rosen A, Pritchett YL, et al. . A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5–15. 10.1016/j.pain.2005.06.031 - DOI - PubMed
    1. Mariappan P, Alhasso A, Ballantyne Z, et al. . Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 2007;51:67–74. 10.1016/j.eururo.2006.08.041 - DOI - PubMed
    1. Mancini M, Perna G, Rossi A, et al. . Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. Expert Opin Pharmacother 2010;11:1167–81. 10.1517/14656561003747441 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources